Nektar Therapeutics Presents New Clinical Data from Ongoing Phase 1 DoseEscalation Study of NKTR214 at the Society for Immunotherapy of Cancer SITC 2016 Annual Meeting

SAN FRANCISCO Nov. 9 2016 PRNewswire Nektar Therapeutics Nasdaq NKTR today announced that new Phase 1 clinical data for Nektar's lead immunooncology agent NKTR214 were presented at the SITC 2016 Annual Meeting. NKTR214 is an investigational immunostimula...